未登录

A

Agnieszka Potęga

Gdansk University of Technology

H指数:10

被引数:278

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Unsymmetrical bisacridines as anticancer drug candidates: structure-metabolism-activity relationships and design principles

非对称双吖啶作为抗癌药物候选物：构型-代谢-活性关系及设计原则

European Journal of Medicinal Chemistry

IF5.9

2026-07-010

OAAI

Electrochemical Simulation of 25B-NBOMe Phase I Metabolism and Metabolite Profiling by HPLC-QTOF-MS

电化学模拟25B-NBOMe的I期代谢及代谢物HPLC-QTOF-MS分析

Molecules 2025, Vol. 30, Page 4450

IF4.6

2025-11-190

OAAI

Distinct cellular uptake patterns of two anticancer unsymmetrical bisacridines and their metabolic transformation in tumor cells

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

IF3.1

2025-01-010

PRE

In vitro biological evaluation of a novel folic acid-targeted receptor quantum dot-β-cyclodextrin carrier for C-2028 unsymmetrical bisacridine in the treatment of human lung and prostate cancers

PHARMACOLOGICAL REPORTS

IF3.8

2024-06-181

OAAI

Electrochemistry/mass spectrometry (EC/MS) for fast generation and identification of novel reactive metabolites of two unsymmetrical bisacridines with anticancer activity

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

IF3.1

2023-10-011

PRE

In Vitro Enzyme Kinetics and NMR-Based Product Elucidation for Glutathione S-Conjugation of the Anticancer Unsymmetrical Bisacridine C-2028 in Liver Microsomes and Cytosol: Major Role of Glutathione S-Transferase M1-1 Isoenzyme

IF4.6

2023-09-261

OAAI

New, fast and cheap prediction tests for BRCA1 gene mutations identification in clinical samples

SCIENTIFIC REPORTS

IF3.9

2023-05-056

OAAI

pH-Responsive Drug Delivery Nanoplatforms as Smart Carriers of Unsymmetrical Bisacridines for Targeted Cancer Therapy

pH响应性药物递送纳米平台作为不对称双吖啶类药物的智能载体用于癌症靶向治疗

IF5.5

2023-01-069

OAAI

Glutathione-Mediated Conjugation of Anticancer Drugs: An Overview of Reaction Mechanisms and Biological Significance for Drug Detoxification and Bioactivation

IF4.6

2022-08-1754

OAAI

Acid-Base Equilibrium and Self-Association in Relation to High Antitumor Activity of Selected Unsymmetrical Bisacridines Established by Extensive Chemometric Analysis

IF4.6

2022-06-217

OAAI

Novel insights into conjugation of antitumor-active unsymmetrical bisacridine C-2028 with glutathione: Characteristics of non-enzymatic and glutathione S-transferase-mediated reactions

JOURNAL OF PHARMACEUTICAL ANALYSIS

IF8.9

2021-12-019

OAAI

Metabolic Profiles of New Unsymmetrical Bisacridine Antitumor Agents in Electrochemical and Enzymatic Noncellular Systems and in Tumor Cells

PHARMACEUTICALS

IF4.8

2021-04-018

OAAI

Electrochemical simulation of metabolic reduction and conjugation reactions of unsymmetrical bisacridine antitumor agents, C-2028 and C-2053

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

IF3.1

2021-04-016

PREAI

Electrochemical and in silico approaches for liver metabolic oxidation of antitumor-active triazoloacridinone C-1305

JOURNAL OF PHARMACEUTICAL ANALYSIS

IF8.9

2020-08-017

OAAI

Electrochemical simulation of metabolism for antitumor-active imidazoacridinone C-1311 and in silico prediction of drug metabolic reactions

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

IF3.1

2019-05-0112

PREAI

Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes

PHARMACOLOGICAL REPORTS

IF3.8

2016-08-016

PREAI

Modulation of CYP3A4 activity and induction of apoptosis, necrosis and senescence by the anti-tumour imidazoacridinone C-1311 in human hepatoma cells

CELL BIOLOGY INTERNATIONAL

IF3.1

2013-01-1413

PREAI

Diminished toxicity of C-1748, 4-methyl-9-hydroxyethylamino-1-nitroacridine, compared with its demethyl analog, C-857, corresponds to its resistance to metabolism in HepG2 cells

BIOCHEMICAL PHARMACOLOGY

IF5.6

2012-07-0110

PREAI